Introduction {#s1}
============

Lipases (triacylglycerol acylhydrolases, EC 3.1.1.3) are ubiquitous enzymes produced by all animals, plants and microbes. Generally, lipases are vital for catalysis of hydrolysis of esters, which are long-chain fatty acids and glycerol in aqueous solutions. And lipases catalyze other reactions in microaqueous and liposoluble environments such as transesterification, alcoholysis, esterification, aminolysis (Gupta et al., [@B16]; Angkawidjaja and Kanaya, [@B2]). The versatility and plasticity of lipases contribute to their extensive application in the production of fine chemicals (Busto et al., [@B6]; Chang et al., [@B7]), detergents (Romdhane et al., [@B34]; Grbavčić et al., [@B15]), food (Aravindan et al., [@B3]; Pan et al., [@B30]), and biodiesel (Yoo et al., [@B44]; Jin et al., [@B20]). Lipases from the genera *Pseudomonas* and *Burkholderia* have high tolerance to harsh industrial application environments (Tran et al., [@B40]; Dwivedee et al., [@B11]). However, Enzyme production is too limited to match the demands of industry because of low lipase expression in original strains.

The lipase genes of *Pseudomonas* and *Burkholderia* species are concurrently transcribed with other genes that encode helper proteins (Rosenau and Jaeger, [@B36]), which are previously known regulators of lipase expression (Frenken et al., [@B13]). However, according to recent studies, the function of lipase helper proteins is mainly effective lipase folding in the periplasm rather than control of regulation (Rosenau and Jaeger, [@B36]). Numerous, extensive studies have investigated the transcriptional regulation mechanisms of operons, including lipase genes in the *lipAB* operon, whose expression is induced by soybean oil in *P. alcaligenes* (Cox et al., [@B9]; Krzeslak et al., [@B21]). Initially, an σ54, RpoN-dependent promoter region and upstream activator sequence (UAS) were recognized in the upstream sequence of the *lipAB* operon and illustrated (Cox et al., [@B9]). This result was followed by identification of LipQR, a two-component regulation system of the operon (Krzeslak et al., [@B21]). There is convincing evidence that after aspartate 52 is phosphorylated, LipR interacts with the UAS of *lipAB*, is initiated and activates transcription of *lipAB*, and RpoN is extensively involved in lipase expression (Krzeslak et al., [@B22]). The transcriptional origin of the lipase operon is downstream of a classical 54-type promoter, with a GG-N10-GC region at transcriptional origins 12--24 in *P. alcaligenes* M-1 (Nirandarjos et al., [@B29]; Deretic et al., [@B10]). These Active components operate together with an UAS of lipase gene that is vital for lipase expression regulation.

The global Gac-Rsm signal transduction system is widely accepted to work effectively in regulating lipase gene expression. GacS-GacA (GacS/A), a two-component regulator system, functions in lipase gene expression in *Pseudomonas* spp. (Reimmann et al., [@B32]; Rosenau and Jaeger, [@B36]; Lalaouna et al., [@B23]), with high conservation of GacS, a sensor kinase that locates and binds to the inner cytomembrane and is activated via autophosphorylation after recognizing ambiguous signals, and GacA, a cognate response regulator is evoked by phosphorylated GacS via phosphorylation. The transcription of multiple small regulatory RNAs (sRNAs) such as RsmY, RsmX, and RsmZ in *P. protegens* or RsmY and RsmZ in *P. aeruginos*a is assumed to be initialized and promoted by activated GacA, based on available models. These sRNAs have multiple single-stranded GGA motifs and high affinities to RNA-binding protein(s) RsmA (and RsmE) from the RsmA-CsrA family. Using titration to identify RNA-binding proteins bound to particular motifs (often GGA or ANGGA) that overlay or are close to the Shine-Dalgarno (SD) sequence of targeted mRNAs, single-stranded GGA motifs can relieve translational repression, so as to enhance translation initiation (Lapouge et al., [@B24]; Brown, [@B5]; Sonnleitner and Haas, [@B38]; Marzi and Romby, [@B27]). RsmA generally suppresses the two QS systems of *P. aeruginos*a. Consequently, extracellular products such as lipases are inhibited. RsmA induces expression of lipases via an unidentified mechanism in *P. aeruginos*a (Heurlier et al., [@B18]; Gooderham and Hancock, [@B14]).

As a two-component regulator system, response regulator PmrA, had a great relationship with downstream genes expression, such as the widely investigated multidrug-resistant genes of *P. aeruginosa* (Ly et al., [@B26]). In this study, a control group (PS1) and an olive oil-induction group (PS2) were used to study lipase gene regulation. When the growth of the strain was in the stable period, the enzyme activity of the induced group was 3.6 times higher than that of the control group. Then, RNA-seq and proteomics were further employed for the regulatory mechanism analysis. Analyzing associations between RNA-seq \[log2 Ratio (PS2/PS1) = 8.8\] and proteomic data \[Quantition(PS2/PS1) = 2.5\] showed that PmrA expression was significantly correlated with *lipA* expression in *P. aeruginosa* PAO1. Furthermore, lipase activity was significantly reduced after the PmrA gene was knocked out. Additionally, our preliminary study also inferred that PmrA might interacted with *rsmY* to control lipase expression in PAO1. Therefore, in this study, the effect of PmrA on *lipA* expression in *P. aeruginosa* PAO1 was systematically investigated via the combined strategy of knocking out and overexpressing *pmrA, rsmY*, and *rsmA*.

Materials and methods {#s2}
=====================

Strains and chemicals
---------------------

Details of bacterial strains and plasmids used in this study are in Table [1](#T1){ref-type="table"}. Propagation of *P. aeruginosa* strains was in liquid or solid LB or M9 minimal (1.5% agar) medium (0.6% Na~2~HPO~4~, 0.3% KH~2~PO~4~, 0.1% NH~4~Cl, 0.05% NaCl, 3 × 10^−4^% CaCl~2~, 1 mL 1 mol/L MgSO~4~·7H~2~O, 10 mL 20% glucose). *Escherichia coli* strains were propagated in LB medium (1.5% agar). The antibiotics used were kanamycin (50 μg/mL) and carbenicillin (100 μg/mL) for *P*. *aeruginosa*, and ampicillin (100 μg/mL) and tetracycline (25 μg/mL) for *E. coli*. PrimeSTAR HS DNA polymerase, DNA ligation kits and restriction enzymes were purchased from TaKaRa Biotechnology (Dalian, China). Kits for extracting genomic DNA, DNA gel and preparing plasmids (Omega Bio-Tek, Doraville, GA, USA) were used according to the manufacturer\'s instructions. DNA fragments were sequenced by Shanghai Sunny Biotechnology (Shanghai, China). Primers were synthesized by Wuhan Anygene Biological Technology (Wuhan, China). Other regular methods were completed according to defined protocols.

###### 

Strains and plasmids used in this study.

  **Strains and plasmids**             **Description**                                                                                                                     **Reference**
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------- ---------------
  ***E. COLI***                                                                                                                                                            
  Top10                                *mcrA*\_x*0003(mrr-hsdRMS*-mcrB*C)*\_x0004*80lacZM15_x0*00*3lacX7*4 *recA1 araD139(ara-leu)7697 galU galK rpsL (Strr) endA1 nupG*   Invitrogen
  BL21(DE3)                            F_x*0005_omp*T hsdSB(rB\_*x0005*\_mB) dcm gal(DE3)                                                                                  Novagen
  BL/pET-28a                           BL21(DE3) with pET-28a; Kmr                                                                                                         This study
  BL/pET-PmrA                          BL21(DE3) with pET-PmrA; Kmr                                                                                                        This study
  ***P. AERUGINOSA***                                                                                                                                                      
  PAO1                                 Wild strain                                                                                                                         
  PA101                                ΔlipC derivative of PAO1; Apr                                                                                                       This study
  PA102                                ΔPmrA derivative of PA101; Apr                                                                                                      This study
  PA104                                ΔrsmY derivative of PA101; Apr                                                                                                      This study
  PA105                                ΔrsmA derivative of PA101; Apr                                                                                                      This study
  PA101A3                              pJQ001 conjugated into PA101; Gm                                                                                                    This study
  PA101A4                              pJQ002 conjugated into PA101; Gm                                                                                                    This study
  PA102A3                              pJQ001 conjugated into PA102; Gm                                                                                                    This study
  PA102A4                              pJQ002 conjugated into PA102; Gm                                                                                                    This study
  PA104A3                              pJQ001 conjugated into PA104; Gm                                                                                                    This study
  PA104A4                              pJQ002 conjugated into PA104; Gm                                                                                                    This study
  PA105A3                              pJQ001 conjugated into PA105; Gm                                                                                                    This study
  PA105A4                              pJQ002 conjugated into PA105; Gm                                                                                                    This study
  **PLASMIDS**                                                                                                                                                             
  Triparental mating, pRK2073          Helper plasmid for triparental mating; Spr                                                                                          
  **MARKERLESS DELETION MUTATION**                                                                                                                                         
  pJQ200SK                             Suicide vector with *sacB* counterselectable marker used for homologous recombination; Gmr                                          
  pJQΔlipC                             pJQ200SK carrying a 2-kb upstream and downstream homologous arm of the coding region of *lipC*; Gmr                                 This study
  pJQΔPmrA                             pJQ200SK carrying a 1.4-kb upstream and downstream homologous arm of the coding region of *PmrA*; Gmr                               This study
  pJQΔrsmY                             pJQ200SK carrying a 300-bp upstream and downstream homologous arm of the coding region of *rsmY*; Gmr                               This study
  pJQΔrsmA                             pJQ200SK carrying a 400-bp upstream and downstream homologous arm of the coding region of *rsmA*; Gmr                               This study
  **OVEREXPRESSION**                                                                                                                                                       
  pBBR1MCS-5                           Broad-host-range vector; Gmr                                                                                                        
  pBBRPmrA                             PBBR1MCS-5 with a 666-bp EcoRI-XbaI fragment harboring the coding region of *PmrA*; Gm                                              This study
  pBBrsmY                              PBBR1MCS-5 with a 666-bp EcoRI-XbaI fragment harboring the coding region of *PmrA*; Gm                                              This study
  pBBRrsmA                             PBBR1MCS-5 with a 666-bp EcoRI-XbaI fragment harboring the coding region of *PmrA*; Gm                                              This study
  pET-28a                              Expression vector carrying an N-terminal His tag-thrombin-T7 tag configuration plus an optional, C-terminal His tag sequence; Kmr   Novagen
  pETPmrA                              pET-28a carrying a 666-bp NdeI-XhoI fragment harboring the coding region of *PmrA*; Kmr                                             
  **CHROMOSOME-BORNE *lacZ* FUSION**                                                                                                                                       
  pJQ001                               pJQ200SK derivative with a translational *lipA-lacZ* fusion; Gmr                                                                    This study
  pJQ002                               pJQ200SK derivative with a translational *lipA\'-\'lacZ* fusion; Gmr                                                                This study
  pJQ003                               pJQ200SK derivative with a translational *rsmA-lacZ* fusion; Gmr                                                                    This study
  pJQ004                               pJQ200SK derivative with a translational *rsmA\'-\'lacZ* fusion; Gmr                                                                This study

Construction of mutation plasmid
--------------------------------

Homologous sequences 1,000 bp upstream and 1,000 bp downstream of *lipC* were used to produce a markerless deletion-mutant system for the coding area by overlapping PCR. The *Xba*I-*Bam*HI-digested mutant system and suicide plasmid pJQ200SK (Quandt and Hynes, [@B31]) were ligated and transformed into *E. coli*. Transformants were spread on LB medium with 50 μg/ml gentamicin. A PCR-confirmed recombinant plasmid was isolated and sequenced and named as pJQΔlipC (Table [1](#T1){ref-type="table"}). Homologous sequences 700 bp upstream and 700 bp downstream of *pmrA*, 150 bp upstream and 150 bp downstream of *RsmY*, or 200 bp upstream and 200 bp downstream of *rsmA* were ligated into the suicide plasmid pJQ200SK to construct pJQΔPmrA, pJQΔRsmY, pJQΔrsmA, respectively.

Construction of expression plasmids
-----------------------------------

*Bam*HI and *Xba*I were used to excise the coding areas of *PmrA* (666 bp), *rsmY* (124 bp), and *rsmA* (186 bp), which were cloned into plasmid pBBR1MCS-5 to create recombinant plasmids pBBRPmrA, pBBRrsmY, and pBBRrsmA. In a similar method, *Nde*I and *Hin*dIII were used to digest the coding sequences of *rsmA* (186 bp) to create plasmid pET-rsmA (Table [1](#T1){ref-type="table"}).

Construction of lacZ-fusion plasmids
------------------------------------

To construct translationally and transcriptionally fused *lipA*-*lacZ* and *lipA\'*-'*lacZ*, amplicons of wild-type *lacZ*, containing the SD sequence, and '*lacZ*, whose SD sequence as well as the first six codons were absent, were obtained from the genome of *E. coli* BL21(DE3) by amplification. Amplicons of *lipA* and *lipA\'* were acquired in a similar method. The *lacZ* and *lipA* fragments were digested and cloned into plasmid pJQ200SK for a translationally fused plasmid pJQ001; '*lacZ* and *lipA\'* were digested and cloned into plasmid pJQ200SK for a transcriptionally fused plasmid pJQ002 (Table [1](#T1){ref-type="table"}). To construct *rsmA*-*lacZ* and *rsmA\'*-'*lacZ* translational-transcriptional fusions (Figure [1](#F1){ref-type="fig"}), amplicons of *rsmA* and *lacZ* were digested and cloned into plasmid pJQ200SK to construct translationally fused plasmid pJQ003; amplicons of *rsmA\'* and '*lacZ* were cloned into pJQ200SK for transcriptionally fused plasmid pJQ004 (Table [1](#T1){ref-type="table"}). Regular forward primer and specific reverse primers containing targeted replacement sequences were designed to generate single-base substitution mutations in the AGAUGA motif of the *lipA* mRNA SD sequence (Table [2](#T2){ref-type="table"}).

![Schematic diagram of *lacZ* transcriptional fusion **(A)** and '*lacZ* translational fusion **(B)**. **(A)** Transcriptional control of *lacZ* depended on the *x* promoter (P). Translational product was a hybrid protein containing some upstream amino acids of X coding region and a functional component of β-galactosidase. Promoter strength and effectiveness of inducing translation of the target gene was reflected by the information of the translational fusion. **(B)** Translational control of '*lacZ* relied on the *x* promoter (P). Translational product was a hybrid protein containing some upstream amino acids of X coding region and the first codon of X, as well as a large functional component of β-galactosidase at C-terminal. Promoter strength of the corresponding gene was reflected in the information of the translational fusion.](fmicb-08-02690-g0001){#F1}

###### 

Primers used in this study.

  **Gene and prime name**                                       **Sequence(5^′^--3^′^)**
  --------------------------------------------- --------------- ---------------------------------------
  **MARKERLESS DELETION MUTATION**                              
  **Markerless deletion mutation**, Δ**lipC**                   
  lipC1                                                         GC[TCTAGA]{.ul}CGCCGGATGCCGCGGACGATCT
  lipC2                                                         CGTCGAGACTCCGTTCGGATTG
  lipC3                                                         AACGGAGTCTCGACGTCCGCTCGCCGGGTCGCCGCAG
  lipC4                                                         CG[GGATCC]{.ul}GCCCATGATCAGCACCAAATCG
  **Markerless deletion mutation**, Δ**PmrA**                   
  PmrA1                                                         CG[GGATCC]{.ul}AGACGCGGAACTGCCGGAGAC
  PmrA2                                                         GGCAGCCTCGTTTCAGTGATT
  PmrA3                                                         TGAAACGAGGCTGCCAAACTGCCTACCGGAGTCCCC
  PmrA4                                                         CCG[CTCGAG]{.ul}AGTTCGTCGATGAGGCCGCGG
  **Markerless deletion mutation**, Δ**rsmY**                   
  rsmY1                                                         CG[GGATCC]{.ul}AGATCATCTTGACGCACGGCA
  rsmY2                                                         GGTTTGAAGATTACGCATCTC
  rsmY3                                                         CGTAATCTTCAAACCTTATTGCCCGAGGAAAACCGC
  rsmY4                                                         CCG[CTCGAG]{.ul}GCTGCTGTGGAAACCGCTCAG
  **Markerless deletion mutation**, Δ**rsmA**                   
  rsmA1                                                         GC[TCTAGA]{.ul}GCGACAGGGTGAGTGACGCTG
  rsmA2                                                         TCCTTTCTCCTCACGCGAATA
  rsmA3                                                         CGTGAGGAGAAAGGATTTTTATCTAATTTTCCCTTT
  rsmA4                                                         CCG[CTCGAG]{.ul}AGTTACCAAGATGGCTTTCGC
  **OVEREXPRESSION**                                            
  *PmrA*                                        PmrAF           CG[GGATCC]{.ul}ATGAGAATACTGCTGGCCGAG
                                                PmrAR           GC[TCTAGA]{.ul}TCAGGGCGCCGGCTGGTCGAT
  *rsmY*                                        rsmYF           CG[GGATCC]{.ul}GTCAGGACATTGCGCAGGAAG
                                                rsmYR           GC[TCTAGA]{.ul}AAAACCCCGCCTTTTGGGCGG
  *rsmA*                                        rsmAF           CG[GGATCC]{.ul}ATGCTGATTCTGACTCGTCGG
                                                rsmAR           GC[TCTAGA]{.ul}TTAATGGTTTGGCTCTTGATC
  *lacZ*                                        lacZF-BamHI     GAA[GGATCC]{.ul}GAAATACGGGCAGACAT
                                                lacZF-HindIII   GGA[AAGCTT]{.ul}CTGGCCGTCGTTTTACAA
                                                lacZR-HindIII   CGA[AAGCTT]{.ul}CACACAGGAAACAGC
  ***lacZ*** **FUSION**                                         
  lacZ                                          lacZF           CCC[AAGCTT]{.ul}AATTTCACACAGGAAACAGCT
                                                lacZR           CCG[CTCGAG]{.ul}CGAAATACGGGCAGACATGGC
                                                'lacZF          CCC[AAGCTT]{.ul}TCACTGGCCGTCGTTTTACAA
                                                lacZR           CCG[CTCGAG]{.ul}CGAAATACGGGCAGACATGGC
  lipAP                                         lipAPF          CG[GGATCC]{.ul}CACGCGCATCCTAGAAAAGCC
                                                lipAPR          CCC[AAGCTT]{.ul}TGATGGGGCCGAGGGGCGCGT
  lipAP′                                        lipAP′F         CG[GGATCC]{.ul}CACGCGCATCCTAGAAAAGCC
                                                lipAP′R         CCC[AAGCTT]{.ul}CAGAGACTTCTTCTTCATGTT
  rsmYP                                         rsmYPF          GC[TCTAGA]{.ul}GCGACAGGGTGAGTGACGCTG
                                                rsmYPR          CCC[AAGCTT]{.ul}ATATTTCAGGACAACAGTCTG
  rsmYP′                                        rsmYP′F         GC[TCTAGA]{.ul}GCGACAGGGTGAGTGACGCTG
                                                rsmYP′R         CCC[AAGCTT]{.ul}TACCATCAGGGTCTCTCCGAC
  **qRT-PCR**                                                   
  *lipA*                                        qlipAF          TACACCCAGACCAAATACC
                                                qlipAR          AATGCCGAACCAGTAGTC
  *rsmY*                                        qrsmYF          GCCAAAGACAATACGGAAACT
                                                qrsmYR          GCAGACCTCTATCCTGACAT
  *rsmZ*                                        qrsmZF          GTACAGGGAACACGCAAC
                                                qrsmZR          CCTCGTCATCATCCTGAT
  *rsmA*                                        qrsmAF          GAAGGAAGTCGCCGTACA
                                                qrsmAR          TAATGGTTTGGCTCTTGATCTTTC

*The underline represents the restriction enzyme cutting site*.

Construction of strains
-----------------------

Because PAO1 has two main types of lipases---lipA and lipC---we built a mutant to eliminate the disturbance. A double-crossover recombination system with gene substitution was used to construct a mutant with markerless deletions of *lipC* in plasmid pJQΔlipC (Quandt and Hynes, [@B31]; Zha et al., [@B45]), which was named PA101. Similarly, a mutant of PA101 with markerless deletions of the *PmrA* coding area was named as PA102, a mutant of PA101 with markerless deletions of the *rsmY* coding area was named as PA104, a mutant of PA101 with markerless deletions of the *rsmA* coding area was named as PA105, a mutant of PA101 with double markerless deletions of the *PmrA*/rsmY coding area was constructed, and named PA106. Plasmids were transformed into *P*. *aeruginosa* with pRK2073 as a helper plasmid (Leong et al., [@B25]) by triparental mating.

β-galactosidase activity assays
-------------------------------

Miller\'s method was used to detect β-galactosidase activity in indicated *E. coli* and *P. aeruginosa* strains with a chromosomal-fused *lacZ* on *o*-nitrophenyl--D-galactopyranoside (Miller, [@B28]), with normalization of optical density at 600 nm (OD~600~) to bacterial medium. Data are shown in Miller units. When culturing strains containing pBBR1MCS-5 or pET-28a derivatives, we added isopropyl-D-thiogalactopyranoside (TPTG) (0.1 mM) to the medium for expression induction.

QRT-PCR analysis
----------------

Total RNA was isolated from *P. aeruginosa* strains without a chromosomal-fused *lacZ* (OD~600~ = 2.5) cultured in LB medium at 37°C using an RNA pure Bacteria kit (DNase I) (CWBIO, Beijing, China). In accordance with the protocols, reverse transcription into complementary DNA was performed with RevertAid first-strand cDNA synthesis kits (Thermo Scientific). For qRT-PCR, reactions were 20 mL (10 mL SYBR Green Master Mix, 10 pM each primer, 10 ng final cDNA and specific volume of RNase-free water) for a ABI 7500 Real Time PCR machine (Applied Biosystems, Foster City, CA, USA). Each plate contained three technical replicates. *RpoD* was the internal control.

Protein expression and purification
-----------------------------------

After amplification using primers PmrAF and PmrAR, PCR products were inserted into pET-28a(+) digested with *Nde*I and *Hin*dIII to add a carboxyl terminal 6-his-tag. Plasmids were transformed into the expression strain *E. coli* BL21 (DE3) and cultured in LB medium (5 ml) at 37°C overnight. Cells were diluted 1:100 into 1 L LB broth containing ampicillin and cultured. When OD~600~ was between 0.4 and 0.5, recombinant PmrA was activated with 0.1 mM IPTG at 16°C for 20 h.

Mixtures were centrifuged at 7,000 × g for 20 min at 4°C and resuspended in lysis solution, followed by harvest of 6 L of cells and disruption by a One Shot Cell Disrupter (Constant Systems, Daventry, UK). To isolate insoluble substances, mixtures were passed through 0.45-μm syringe-end filters after centrifuging at 12,000 × g for 20 min at 4°C before loading on a His-tag column. Supernatants were transferred to a Ni-NTA affinity chromatography column (GE Healthcare, Pittsburgh, PA, USA). After balancing the column with lysis buffer, recombinant protein was added and eluted using washing buffer with an imidazole concentration gradient (0, 30, 60, 100, 200, and 500 mM). Washing buffer (30 ml) containing target recombinant proteins was dialyzed in 20 mM Tris-HCl, pH 8.0. Proteins were subjected to SDS-PAGE. Unstained and prestained protein markers (Fermentas, SM0431 and SM0671 Waltham, USA) were applied as references.

Electrophoretic mobility shift assays
-------------------------------------

Light Shift Chemiluminescent EMSA kits were used for electrophoretic mobility shift assays (EMSAs). DNA fragments of *rsmY, rsmZ, and rsmA* were synthesized and labeled with biotin; 2 μl biotin-labeled DNA probe was incubated with 3 μl purified PmrA protein (1 mg/ml) in 10 μl binding solution (100 mM HEPES, pH 7.3 with 200 mM KCl, 10 mM MgCl^2^, and 10 mM DTT) at room temperature for 10 min, to eliminate nonspecific binding of probe and protein. A labeled probe was added and mixed at room temperature for 20 min. For competition experiments, unlabeled probe concentrations were 50, 100, and 150 times the labeled probe concentration. One microliter of binding buffer (10x) was added and mixed immediately. Pre-electrophoresis was performed for 30 min with 0.5 x TBE as the electrophoretic solution, at 80 V. Separated protein-DNA conjugates were electrophoretically transferred to nylon membranes with positive charges (Ambion) using a semidry transfer instrument (Tanon). UV light at 320 nm was used to crosslink transferred PmrA-DNA complexes and free DNA to membranes. A chemiluminescent nucleic acid detection module (Thermo Scientific) was used to detect biotin-labeled bands. To probe DNAs labeled with biotin on nylon membranes, streptavidin-horseradish peroxidase (HRP) conjugates were employed. HRP catalyzed an enhanced luminol-based substrate for optimal block, followed by washing to obtain light-sensitive. Membranes were set in film cassettes in light and exposed to X-ray film for 20--30 s.

Lipase activity assay
---------------------

Supernatant lipase activity was used to detect LipA, an extracellular lipase (Wohlfarth et al., [@B42]). Mixtures (OD~600~ 2.5) of *P. aeruginosa* strains without chromosomally fused *lacZ* were cultured in LB medium at 37°C. Supernatants were collected and lipase activities of *p*-nitrophenyl caprylate (*p*NPC) were assessed by spectrophotometry (Yang et al., [@B43]), with some modifications. The system was 2.9 ml Tris-HCl buffer (50 mM, pH 9.0) and 30 μl *p*NPC (10 mM *p*NPC in acetonitrile). After preincubating at 40°C for 5 min, 70 μl supernatant was added. Mixtures were incubated at 40°C for 5 min, followed by centrifugation (12,000 r/m, 2 min, 4°C) and OD~410~ measurement. The definition of one unit lipase activity was the amount of enzyme needed to release 1 mol *p*-nitrophenol per minute by 1 ml sample with OD~600~ 1.0. The activity of bacterial lipase was shown in U/ml · OD~600~.

Statistical analysis
--------------------

Two-tailed, unpaired Student\'s *t-*tests were used to calculate *P-*values, with \< 0.05 considered statistically significant.

Results {#s3}
=======

PmrA activates transcription and translation of lipA
----------------------------------------------------

To eliminate interference from lipase lipC in studying the regulation of lipase expression, a lipC-mutant strain P101 was constructed. It was found that enzyme activity had little change in the lipC-mutant strain P101 (Figure [2A](#F2){ref-type="fig"}). Thus, the effect of lipC on the enzyme activity measurement of LipA could be ruled out. To study PmrA in regulation of lipA expression in PAO1, a gene replacement system with plasmid pJQΔPmrA was used to construct the PmrA deletion mutant PA102. A significant reduction in enzyme activity was observed in the PmrA-deletion mutant PA102 (Figure [2A](#F2){ref-type="fig"}). The results on transcription of *lipA* by qRT-PCR in PAO1, PA101, and PA102 were consistent with the relative extracellular lipase activities (Figures [2A,B](#F2){ref-type="fig"}). To further investigate the regulating mechanism of PmrA-activated expression of *lipA*, expression of chromosome-borne *lipA-lacZ* and *lipA\'-'lacZ* fusions was assessed in PA101 and PA102. As a result, PmrA positively regulated the expression of *lipA* both transcriptionally and translationally, and the latter appeared to be the core regulating mechanism (Figure [2C](#F2){ref-type="fig"}). To examine the influence of PmrA overexpression on expression of *lipA* in PA101 and PA102, PmrA was overexpressed in PA101 and PA102 via the PmrA expression plasmid pBBBRPmrA. PA101/pBBR1MCS-5 was the control. Expression of *lipA* in PA101/pBBRPmrA was higher than in PA101/pBBR1MCS-5 or PA102/pBBR1MCS-5 (Figure [2D](#F2){ref-type="fig"}). Interestingly, despite the close levels of *lipA* expression in PA101/pBBRPmrA and PA102/pBBRPmrA, the expression of *lipA* in PA101/pBBRPmrA was higher than in PA102/pBBRPmrA (Figure [2D](#F2){ref-type="fig"}). In conclusion, there is a great positive correlation between the expression of *lipA* and the expression of PmrA, the expression of *lipA* is regulated by PmrA.

![Effect of PmrA on *lipA* expression. **(A)** Relative lipase activity in PA01, PA101, and PA102. **(B)** QRT-PCR of *lipA* in PA01, PA101, and PA102. **(C)** Effect of *pmrA* mutant on expression of translationally fused, chromosome-borne *lipA*\'-'*lacZ* (control, PA101A4; *pmrA* mutant, PA102A4) and transcriptionally fused chromosome-borne *lipA-lacZ* (control, PA101A3; *pmrA* mutant, PA102A3). After inoculating β-galactosidase into M9 medium (50 mL), activity of strains was determined in stationary phase. **(D)** Relative lipase activity in control strain (PA101) and *pmrA* mutant (PA102). Experiments were in triplicate. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 compared with control group.](fmicb-08-02690-g0002){#F2}

PmrA affects RsmY/Z/A expression
--------------------------------

To study how PmrA acted on expression of *lipA*, the interaction of PmrA with functional genes *rsmY, rsmZ*, and *rsmA* was investigated. QRT-PCR was used to determine how *pmrA* deletion changed transcription of *rsmY, rsmZ*, and *rsmA* in PA101 and PA102. Transcription of *rsmY* and *rsmZ* was lower in PA102 than in PA101 (Figure [3A](#F3){ref-type="fig"}), similar to *lipA* expression in PA102 (Figure [2B](#F2){ref-type="fig"}). Transcription of *rsmA* in PA102 was slightly higher than in PA101. To study the interaction between PmrA and *rsmY/Z/A*, PmrA protein was expressed and the binding site of PmrA protein was explored using EMSAs. PmrA protein was expressed using a purified expression system with pET-28a. EMSAs were used to detect if PmrA protein bound to the *rsmY*/*Z*/*A* promoter sequence (Figures [2B,C](#F2){ref-type="fig"}). PmrA protein bound directly to the promoter region of *rsmY*, but not the promoter sequences of *rsmZ* and *rsmA*. Overexpression of *rsmY, rsmZ, rsmA* showed that *rsmY* promoted expression of lipase (Figures [3A,B](#F3){ref-type="fig"}), which was partly consistent with the results in Figure [3E](#F3){ref-type="fig"}. In order to further study the effect of PmrA on the regulation of *lipA* expression in PAO1, a gene replacement system with plasmid pJQΔRsmY was used to construct mutant PA104, and the double mutant PmrA/rsmY was constructed, and named PA106. The relative lipase activity in PA104/pBBRPmrA was significantly higher than that of PA104/pBBR1MCS-5, the relative lipase activity in PA106/pBBRPmrA was significantly higher than that of PA106/pBBR1MCS-5, and PmrA overexpressed strain of PA106 can greatly compensate for the loss of enzyme activity caused by gene knockout (Figure [3F](#F3){ref-type="fig"}). It is likely that PmrA is able to regulate *lipA* expression via *rsmY* and other unclear pathways.

![Effect of PmrA overexpression on *lipA* expression. **(A)** QRT-PCR of *rsmY, rsmZ*, and *rsmA* in control strain (PA101; lane 1) and PmrA mutant strain (PA102; lane 2). Experiments were in triplicate. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 compared with control group. **(B)** SDS PAGE of purified PmrA protein. Lane 1: protein molecular weight marker. Lane 2: whole cell lysate. Lane 3: liquid behind the column. Lane 4: NTA-30. Lane 5: NTA-60. Lane 6: NTA-100. Lane 7: NTA-200. Lane 8: NTA-500. **(C)** EMSA for binding of PmrA to *rsmY/Z/A* promoter sequence. Lane 1: negative control (−). Lane 2: positive control (+). Lane 3: rsmY. Lane 4: rsmY+PmrA. Lane 5: rsmZ. Lane 6: rsmZ+PmrA. Lane 7: rsmA. Lane 8: rsmA+PmrA. **(D)** PmrA protein bound to *rsmY* sequence, following increases in free *rsmY*. Ratios of free *rsmY* to biotin-labeled *rsmY* were 1:1, 50:1, 100:1, and 150:1 in groups 1 through 4. **(E)** Relative lipase activity in control strain (PA101) and overexpression strain (bar 1, control strain PA101/pBBR1MCS-5; bar 2, PA101/pBBRrsmY; bar 3, PA101/pBBRrsmZ; bar 4, PA101/pBBRrsmA). **(F)** Relative lipase activity (bar 1, control strain PA104/pBBR1MCS-5; bar 2, PA106/pBBR1MCS-5; bar 3, PA104/pBBRPmrA; bar 4, PA106/pBBRPmrA). Experiments were completed in triplicate. Experiments were completed in triplicate. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, compared with the control.](fmicb-08-02690-g0003){#F3}

RsmY and RsmA differentially regulate lipA expression
-----------------------------------------------------

The translational regulation of the Gac-Rsm signaling pathway largely depends on RNA-combining proteins from the RsmA-CsrA family in various gamma-proteobacteria (Lapouge et al., [@B24]). For example, the Gac-Rsm regulatory system consists of RsmA and RsmE from the RsmA-CsrA family in *P. protegens* Pf-5 (Reimmann et al., [@B33]). To study the effect of RsmY and RsmA on the regulation of lipA expression in PAO1, a gene replacement system with plasmid pJQΔRsmA was used to construct mutant PA105. The expression of chromosomally fused *lipA*-*lacZ* (A3) and *lipA*\'-'*lacZ* (A4) was evaluated in PA101, PA104, and PA105 to understand the regulatory pathways of RsmY and RsmA on *lipA* expression. The RsmY-mutant weakly decreased transcription of *lipA* and reduced expression of *lipA* at a translational level. Translational control appeared to be the key regulatory pathway (Figure [4A](#F4){ref-type="fig"}). The RsmA-mutant promoted the translation of *lipA* and weakly decreased transcription of *lipA*. Translational control also appeared to be the key regulatory pathway (Figure [4A](#F4){ref-type="fig"}). The relative lipase activities of PA101/pBBR1MCS-5, PA104/pBBR1MCS-5, PA104/pBBRrsmY, PA105/pBBR1MCS-5, and PA105/pBBRrsmA indicated that the RsmY-mutant decreased expression of *lipA*. The expression of RsmY in complement counteracted the decrease caused by gene deletion. The RsmA-mutant promoted expression of *lipA*. The expression of RsmA in complement counteracted the increase caused by gene deletion (Figure [4B](#F4){ref-type="fig"}). QRT-PCR showed the RsmA-mutant increased *lipA* transcription, and the RsmY-mutant repressed *lipA* transcription (Figure [4C](#F4){ref-type="fig"}). Together, RsmY and RsmA differentially regulated the expression of *lipA*. RsmY increased lipase expression, and RsmA inhibited lipase expression, exhibiting different regulatory patterns in *P. aeruginosa* PAO1.

![Effect of rsmY and rsmA mutants on lipA expression. **(A)** Effect of rsmY and rsmA mutants on expression of chromosome-located translationally fused lipA-lacZ (bar 1, control strain PA101A3; bar 2, rsmY-mutant strain PA104A3; bar 3, rsmA-mutant strain PA105A3) and chromosome-located transcriptionally fused lipA\'-'lacZ (bar 4, control strain PA101A4; bar 5, rsmY-mutant strain PA104A4; bar 6, rsmA-mutant strain PA105A4). After inoculating β-galactosidase into M9 medium (50 ml), the activity of strains was determined in stationary phase. **(B)** Relative lipase activity in PA101/pBBR1MCS-5, PA104/pBBR1MCS-5, PA104/pBBRrsmY, PA105/pBBR1MCS-5, and PA105/pBBRrsmA. **(C)** Expression of *lipA* in wild-type strain PA101 (lane 1), PA104 (lane 2) and PA105 (lane 3) by qRT-PCR. Experiments were in triplicate. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01 compared with control strain.](fmicb-08-02690-g0004){#F4}

RsmY activates lipA translation by inhibiting RsmA translation
--------------------------------------------------------------

To investigate the influence of RsmY on rsmA expression, we analyzed expression of chromosomally fused *rsmA*\'-'*lacZ* (C4). Transcription level of *rsmA* was investigated by qRT-PCR of PA101 and P104. The RsmY-mutant PA104 significantly stimulated expression of *rsmA*. Expression of RsmY in complement counteracted the increase caused by gene deletion (Figure [5A](#F5){ref-type="fig"}). By qRT-PCR, the RsmY-mutant repressed *rsmA* transcription and RsmY transcriptionally regulated *rsmA* (Figure [5B](#F5){ref-type="fig"}). The results implied RsmY repressed *rsmA* translation.

![Effect of rsmY-mutant on *rsmA* expression. **(A)** Effect of rsmY mutant on expression of chromosome-borne translationally fused *rsmA*\'-'*lacZ* (bar 1, control strain PA101C4/pBBR1MCS-5; bar 2, rsmY-mutant strain PA104C4/ pBBR1MCS-5; bar 3, rsmY-overexpression strain PA104C4/pBBRrsmY). **(B)** *rsmA* expression in control strain PA101 (lane 1) and rsmY-mutant strain PA104 (lane 2) by qRT-PCR. Experiments were in triplicate. ^\*^*P* \< 0.05 compared with control.](fmicb-08-02690-g0005){#F5}

RsmA suppresses lipA translation by binding to the SD sequence of lipA mRNA
---------------------------------------------------------------------------

In the literature, RsmE binding to the consensus sequence (A/U)CANGG ANG(U/A) is involved in translation suppression mediated by RsmE by overlapping the SD sequence of targeted mRNA. Binding inhibits recruiting the 30S ribosomal subunit and translation (Schubert et al., [@B37]; Lapouge et al., [@B24]; Wang et al., [@B41]). The protein-RNA interplay between consensus sequence and RsmE has been investigated in *P. protegens* CHA0, which is the same as RsmE from *P. protegens* Pf-5 (Reimmann et al., [@B33]; Schubert et al., [@B37]). We hypothesized a site of action between RsmA and the SD sequence of lipA. Six single-base mutations at nucleotides U(-12), C(-11), U(-10), A(-9), C(-8), G(-7) \[A-U, G-C, A-U, U-A, G-C, A-G\] of lipA mRNA were constructed in plasmid-borne lipA\'-'lacZ fusions that were introduced into *E. coli* BL21(DE3) with plasmid pET-rsmA or pET-28a. The effects of U(-12), C(-11), U(-10), A(-9), C(-8), G(-7) mutations on translational regulation by RsmA are in Table [3](#T3){ref-type="table"}. All mutations influenced regulatory control of RsmA. The suppression of lipA\'-'lacZ fusions by RsmA was eradicated after mutating G(-7), even though RsmA expression was affected by all mutations. Thus, RsmA suppressed the translation of lipA via combination with the AGAUGA sequence.

###### 

Effects of mutations in the SD sequence of lipA mRNA on translational suppression by RsmA.

  **Plasmid**    β**-Galactosidase activity (Miller unites)**   
  -------------- ---------------------------------------------- ---------------
  pBBR003        2435.3 ± 87.5                                  1354.7 ± 69.2
  pBBR00U(-12)   1564.9 ± 75.1                                  826.7 ± 48.6
  pBBR00C(-11)   1847.4 ± 84.7                                  1278.3 ± 72.3
  pBBR00U(-10)   1144.5 ± 83.9                                  667.8 ± 32
  pBBR00A(-9)    1431.4 ± 75.9                                  890.4 ± 60.5
  pBBR00C(-8)    1077.1 ± 90.8                                  734.7 ± 55.4
  pBBR00G(-7)    1665.3 ± 94.5                                  1538.1 ± 83.6

Discussion {#s4}
==========

Many studies indicate a regulatory role for the PmrA/PmrB two-component system (TCS) in the expression of multiple genes. The PmrA/PmrB TCS conducts bacterial responses to multiple stimuli (Hoch, [@B19]), and regulates lipopolysaccharide modifications (Chen and Groisman, [@B8]). Genome-wide microarrays of PmrB and PmrA mutants at exponential and postexponential stages reveal that the PmrA/PmrB TCS affects expression of 279 genes. Affected genes can be categorized into nine groups: type II-secreted proteins, Dot/Icm apparatus and secreted effectors, genes encoding eukaryotic-like proteins, flagellar biosynthesis genes, postexponential phase regulators, metabolic genes, stress response genes, and genes with unknown function (Al-Khodor et al., [@B1]). However, reports are fewer on the regulation of lipase expression by PmrA/PmrB TCS. To find out if PmrA/PmrB TCS regulates lipase expression in PAO1, the *pmrA* gene in PA101 was knocked out and the activity of lipase decreased. Overexpression of *pmrA* in control strain PA101 and mutant PA102 was also established. We found that complementation of *pmrA* restored the activity of lipase and overexpression of *pmrA* enhanced the activity of lipase in control strain PA101. Furthermore, after knocking out *pmrA*, expression of *lipA* also decreased by qRT-PCR. And the lacZ-fusion experiment proved that PmrA positively regulated the expression of *lipA* both transcriptionally and translationally, and the latter appeared to be the core regulating mechanism. Thus, our results suggests that there is a great positive correlation between the expression of *lipA* and the expression of PmrA, the expression of *lipA* is regulated by PmrA (Figure [2](#F2){ref-type="fig"}).

In *P. aeruginosa* PAO1, GacA directly regulates transcription of RsmZ and RsmY to regulate expression of hundreds of genes (Brencic et al., [@B4]). In *P. aeruginosa* PAO1, GacA, and RsmA are competitively associated with RsmY to regulate corresponding gene expression (Sorger-Domenigg et al., [@B39]; Brencic et al., [@B4]). As a defined two-component system, PmrA may be associated with RsmY to regulate gene expression. We studied if PmrA protein bound to the *rsmY/Z/A* promoter sequence. EMSA analysis confirmed that the PmrA protein bound directly to the promoter region of *rsmY*. Together, the results of qRT-PCR, EMSA and the mutant relative lipase activity demonstrated that PmrA is able to regulate *lipA* expression via *rsmY* and other unclear pathways (Figure [3](#F3){ref-type="fig"}).

Analysis of β-galactosidase activity and relative lipase activities in PA101, PA104, and PA105 further indicated that RsmY induced and promoted expression of *lipA*, while RsmA inhibited expression of *lipA*. In addition, analyses of β-galactosidase activity and qRT-PCR in PA101 and PA104 indicated that RsmY repressed *rsmA* transcription. To our knowledge, this is the first clear description of the interaction between PmrA and *rsmY, rsmZ*, and *rsmA* (Figure [4](#F4){ref-type="fig"}).

GGA-motifs are present in *P. aeruginosa* RsmY RNA and they are suggested to be essential for RsmA binding (Heeb et al., [@B17]). The *rsmY* and *rsmA* mutant strains PA104 and PA105 were established to study the effect of Rsm genes on *lipA* expression. Differential regulatory mechanisms were observed for expression of *lipA* regulated by RsmY and RsmA: *lipA* expression was weakly transcriptionally inhibited, but translationally stimulated by RsmY and translation of *lipA* was suppressed by RsmA (Figure [4](#F4){ref-type="fig"}). Generally, Rsm proteins suppress gene expression via translational mechanisms (Lapouge et al., [@B24]; Romeo et al., [@B35]). Our findings are consistent with these results.

The specific mechanism of translational activation by Rsm proteins probably lies in their combination with mRNAs to stabilize and facilitate translation initiation, ultimately leading to positive effects on gene expression (Heurlier et al., [@B18]; Frangipani et al., [@B12]). In a similar manner, CsrA, an ortholog of the Rsm protein family, activates translation initiation after binding to a highly structured untranslated leader of mRNA by changing RNA structure or interaction with a 5′-end-dependent RNase E cleavage pathway of the transcript (50). RsmZ, an antagonist of RsmA, was identified in *P. aeruginosa*. RsmZ and RsmY have similar regulatory functions (Heurlier et al., [@B18]; Brencic et al., [@B4]). We determined that the mechanism adopted by RsmY to activate *lipA* translation depended, at least partially, on suppression of *rsmA* translational expression, in line with the influence of mutant *rsmY* on *rsmA* expression (Figure [5A](#F5){ref-type="fig"}). QRT-PCR results for *rsmA* also showed an inhibitory effect (Figure [5B](#F5){ref-type="fig"}).

Rsm proteins suppress translation mainly through combination with corresponding sites in the initially translated area and/or the untranslated leader of targeted mRNAs, either overlapping the cognate SD sequence (Sonnleitner and Haas, [@B38]; Marzi and Romby, [@B27]). RsmE from *P. protegens* CHA0 is reported to be the same as that from *P. protegens* Pf-5, identifying a consensus sequence of (A/U) CANGGANG (U/A) overlaying the SD sequence of targeted mRNAs (Reimmann et al., [@B33]; Schubert et al., [@B37]). We hypothesized a site of action between RsmA and the SD sequence of lipA. The interaction between RsmA and the SD sequence was verified by mutational analysis of the SD sequence in *lipA* mRNA (Table [3](#T3){ref-type="table"}). The results indicated that PmrA activated lipA translation via a combination of RsmA and the SD sequence in *lipA* mRNA, and the formation of the PmrA-RsmA system, leading to direct translational activation of *lipA* in *P. aeruginosa* PAO1.

Conclusion {#s5}
==========

Transcription of RsmY depended on the presence of PmrA. The function of sRNAs is to relieve translational repression of RNA-binding protein RsmA. RsmY mainly activated *lipA* translation by inhibiting *rsmA* translation. However, RsmA inhibited *lipA* translation by binding to the SD sequence of *lipA* mRNA. Among these regulatory pathways, the RsmA-mediated pathway had the greatest effect on regulation of *lipA* expression (Figure [6](#F6){ref-type="fig"}).

![Schematic diagram of activation of lipA expression by the Pmr-Rsm system in *P. aeruginosa* PAO1. Arrow, positive effect; bar, negative effect.](fmicb-08-02690-g0006){#F6}
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